ABCC1 and asthenia: As for the emergence of asthenia, patients carrying the ABCC1 rs2238476-AG genotype showed a higher risk of having this adverse event during therapy with MTX (OR = 4.70, 95% CI = 1.23–19.87, p = 0.026; Table S20).